Placental disorders in preeclampsia: Maternal and perinatal outcomes

Pregnancy Disorders and Perinatal Outcomes

Volumn , Issue , 2012, Pages 97-128

  Lanoix, Dave ^a,b   Haché, Sophie ^c   Dubé, Evemie ^c   Lafond, Julie ^c   Vaillancourt, Cathy ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b BioMed Research Center   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Fetal development; Intra Uterine Growth Restriction (Iugr); Maternal hypertension; Placenta; Preeclampsia; Proteinuria; Trophoblast

Indexed keywords

EID: 84884450701     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805372811201010097     Document Type: Chapter

References (397)

1. WHO. The World Health Report 2005-make every mother and child count. World Health Organization 2005.
2. World Health Report: Make every mother and child count. Geneva, Switzerland: World Health Organization 2005.
3. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183(1): S1-S22.
4. Chandiramani M, Shennan A. Hypertensive disorders of pregnancy: a UK-based perspective. Curr Opin Obstet Gynecol 2008; 20(2): 96-101.
5. WHO. World Health Organization survey. World Health Organization 2003.
6. Saftlas AF, Levine RJ, Klebanoff MA, et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol 2003; 157(12): 1108-1114.
7. Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95(1): 24-28.
8. Sibai BM, Hauth J, Caritis S, et al. Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000; 182(4): 938-942.
9. Wen SW, Demissie K, Yang Q, Walker MC. Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. Am J Obstet Gynecol 2004; 191(1): 254-258.
10. Chen YY, Wu ML, Kao MH, Su TH, Chen CP. Perinatal outcome of recurrent pre-eclampsia versus pre-eclampsia in nulliparas. J Obstet Gynaecol Res 2009; 35(6): 1042-1046.
11. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002; 100(2): 369-377.
12. Marik PE. Hypertensive disorders of pregnancy. Postgrad Med 2009; 121(2): 69-76.
13. Rath W, Fischer T. The diagnosis and treatment of hypertensive disorders of pregnancy: new findings for antenatal and inpatient care. Dtsch Arztebl Int 2009; 106(45): 733-738.
14. Howarth C, Gazis A, James D. Associations of Type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. Diabet Med 2007; 24(11): 1229-1234.
15. Peticca P, Keely EJ, Walker MC, Yang Q, Bottomley J. Pregnancy outcomes in diabetes subtypes: how do they compare?. A province-based study of Ontario, 2005-2006. J Obstet Gynaecol Can 2009; 31(6): 487-496.
16. McDonald SD, Best C, Lam K. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. BJOG 2009; 116(12): 1578-1584.
17. Lykke JA, Paidas MJ, Langhoff-Roos J. Recurring complications in second pregnancy. Obstet Gynecol 2009; 113(6): 1217-1224.
18. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009; 338: b2255.
19. Kahn SR, Platt R, McNamara H, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol 2009; 200(2): 151e1-9; discussion e1-5.
20. Kupferminc MJ. Thrombophilia and pregnancy. Obstet Gynecol 2005; 48(2): 406-415.
21. Jahromi BN, Husseini Z. Pregnancy outcome at maternal age 40 and older. Taiwan J Obstet Gynecol 2008; 47(3): 318-21.
22. Najati N, Gojazadeh M. Maternal and neonatal complications in mothers aged under 18 years. Patient Prefer Adherence 2010; 21(4): 219-22.
23. Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol 2005; 162(12): 1198-206.
24. Bodnar LM, Ness RB, Markovic N, Roberts JM. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol 2005; 15(7): 475-82.
25. Walsh SW. Obesity: a risk factor for preeclampsia. Trends Endocrinol Metab 2007; 18(10): 365-70.
26. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001; 357(9251): 209-215.
27. Lie RT. Intergenerational exchange and perinatal risks: a note on interpretation of generational recurrence risks. Paediatr Perinat Epidemiol 2007; 21(Suppl 1): 13-8.
28. Horton AL, Boggess KA, Moss KL, Beck J, Offenbacher S. Periodontal disease, oxidative stress, and risk for preeclampsia. J Periodontol 2010; 81(2) :199-204.
29. Pouliot SH, Xiong X, Harville E, et al. Maternal dengue and pregnancy outcomes: a systematic review. Obstet Gynecol Surv 2010; 65(2): 107-118.
30. Nguyen G, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009; 29(7): 755-764.
31. Ciarmela P, Boschi S, Bloise E, et al. Polymorphisms of FAS and FAS ligand genes in preeclamptic women. Eur J Obstet Gynecol Reprod Biol 2010; 148(2): 144-146.
32. Zusterzeel PL, Peters WH, Burton GJ, Visser W, Roelofs HM, Steegers EA. Susceptibility to pre-eclampsia is associated with multiple genetic polymorphisms in maternal biotransformation enzymes. Gynecol Obstet Invest 2007; 63(4): 209-213.
33. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG 2004; 111(3): 200-206.
34. Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92(2): 131-40.
35. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002; 346(1): 33-38.
36. Dekker G. The partner's role in the etiology of preeclampsia. J Reprod Immunol 2002; 57(1-2): 203-215.
37. Robillard PY, Hulsey TC. Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception. Lancet 1996; 347(9001): 619.
38. Salha O, Sharma V, Dada T, et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod 1999; 14(9): 2268-2273.
39. Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 2002; 359(9307): 673-674.
40. Chen XK, Wen SW, Bottomley J, Smith GN, Leader A, Walker MC. In vitro fertilization is associated with an increased risk for preeclampsia. Hypertens Pregnancy 2009; 28(1): 1-12.
41. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009; 200(5): 481e1-7.
42. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51(4): 970-975.
43. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003; 22(2): 143-148.
44. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77(1): 67-75.
45. Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician 2004; 70(12): 2317-2324.
46. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46(6): 1243-1249.
47. Rockwell LC, Vargas E, Moore LG. Human physiological adaptation to pregnancy: inter-and intraspecific perspectives. Am J Hum Biol 2003; 15(3): 330-341.
48. Thaler I, Manor D, Itskovitz J, et al. Changes in uterine blood flow during human pregnancy. Am J Obstet Gynecol 1990; 162(1): 121-125.
49. Kliman HJ. Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion. Am J Pathol 2000; 157(6): 1759-1768.
50. Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46(5): 1123-1128.
51. Easterling TR. The maternal hemodynamics of preeclampsia. Clin Obstet Gynecol 1992; 35(2): 375-386.
52. Lunell NO, Nylund LE, Lewander R, Sarby B. Uteroplacental blood flow in pre-eclampsia measurements with indium-113m and a computer-linked gamma camera. Clin Exp Hypertens B 1982; 1(1): 105-117.
53. Halhali A, Wimalawansa SJ, Berentsen V, Avila E, Thota CS, Larrea F. Calcitonin gene-and parathyroid hormonerelated peptides in preeclampsia: effects of magnesium sulfate. Obstet Gynecol 2001; 97(6): 893-897.
54. Meziani F, Van Overloop B, Schneider F, Gairard A. Parathyroid hormone-related protein-induced relaxation of rat uterine arteries: influence of the endothelium during gestation. J Soc Gynecol Investig 2005; 12(1): 14-19.
55. Maioli E, Fortino V, Pacini A. Parathyroid Hormone-Related Protein in Preeclampsia: A Linkage Between Maternal and Fetal Failures. Biol Reprod 2004; 71(6): 1779-1784.
56. Kovacs CS. PTHrP gene knock out mouse have placental calcium transport severely impaired. J Bone Miner Res 1995; 10(S1): 73.
57. Kovacs CS, Lanske B, Hunzelman JL, Guo J, Karaplis AC, Kronenberg HM. Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor. Proc Natl Acad Sci U S A 1996; 93(26): 15233-15238.
58. Nielsen AH, Schauser KH, Poulsen K. Current topic: the uteroplacental renin-angiotensin system. Placenta 2000; 21(5-6): 468-477.
59. Carroli G, Duley L, Belizan JM, Villar J. Calcium supplementation during pregnancy: a systematic review of randomised controlled trials. Br J Obstet Gynaecol 1994; 101(9): 753-758.
60. Hofmeyr GJ, Duley L, Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007; 114(8): 933-943.
61. Gillman MW, Hood MY, Moore LL, Nguyen US, Singer MR, Andon MB. Effect of calcium supplementation on blood pressure in children. J Pediatr 1995; 127(2): 186-192.
62. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2002; (1): CD001059.
63. Nielsen TF, Rylander R. Urinary calcium and magnesium excretion relates to increase in blood pressure during pregnancy. Arch Gynecol Obstet 2011; 283(3): 443-447.
64. Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981; 60(4): 267-76.
65. Gartner HV, Sammoun A, Wehrmann M, Grossmann T, Junghans R, Weihing C. Preeclamptic nephropathy--an endothelial lesion. A morphological study with a review of the literature. Eur J Obstet Gynecol Reprod Biol 1998; 77(1): 11-27.
66. Thornton CE, Makris A, Ogle RF, Tooher JM, Hennessy A. The Role of Proteinuria in Defining Preeclampsia- Clinical Outcomes for Women and Babies. Clin Exp Pharmacol Physiol 2010; 37(4): 466-470.
67. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust N Z J Obstet Gynaecol 2000; 40(2): 133-138.
68. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2002; 20(1): ix-xiv.
69. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997; 157(6): 715-25.
70. Higgins JR, de Swiet M. Blood-pressure measurement and classification in pregnancy. Lancet 2001; 357(9250): 131-135.
71. Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1996; 175(2): 460-464.
72. Brown MA, Zammit VC, Lowe SA. Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. Clin Sci (Lond) 1989; 77(6): 599-604.
73. Robillard PY, Dekker GA, Hulsey TC. Revisiting the epidemiological standard of preeclampsia: primigravidity or primipaternity?. Eur J Obstet Gynecol Reprod Biol 1999; 84(1): 37-41.
74. Sibai BM, Mabie BC, Harvey CJ, Gonzalez AR. Pulmonary edema in severe preeclampsia-eclampsia: analysis of thirty-seven consecutive cases. Am J Obstet Gynecol 1987; 156(5): 1174-1179.
75. Bauer ST, Cleary KL. Cardiopulmonary complications of pre-eclampsia. Semin Perinatol 2009; 33(3): 158-165.
76. Zlatnik MG. Pulmonary edema: etiology and treatment. Semin Perinatol 1997; 21(4): 298-306.
77. Jeffcoate TN. Pre-eclampsia and eclampsia: the disease of theories. Proc R Soc Med 1966; 59(5): 397-404.
78. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta 1991; 12(4): 301-308.
79. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30(Suppl A): S38-42.
80. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30(Suppl A): S32-37.
81. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308(5728): 1592-1594.
82. Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet 1999; 354(9181): 788-789.
83. Redman CW, Sargent IL. Immunology of Pre-Eclampsia. Am J Reprod Immunol 2010; 63(6): 534-543.
84. Redman CW. Preeclampsia: a multi-stress disorder. Rev Med Interne 2011; (32 Suppl 1): S41-4.
85. Eardley H. Recent Work on the Etiology of Eclampsia. BJOG 1909; 16(6): 384-400.
86. Chun D, Braga C, Chow C, Lok L. Clinical Observations on Some Aspects of Hydatidiform Moles. J Obstet Gynaecol Br Commonw 1964; 71: 180-184.
87. Shembrey MA, Noble AD. An instructive case of abdominal pregnancy. Aust N Z J Obstet Gynaecol 1995; 35(2): 220-221.
88. Piering WF, Garancis JG, Becker CG, Beres JA, Lemann J, Jr. Preeclampsia related to a functioning extrauterine placenta: report of a case and 25-year follow-up. Am J Kidney Dis 1993; 21(3): 310-313.
89. Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol 2004; 190(5): 1464-1466.
90. Matsuo K, Kooshesh S, Dinc M, Sun CC, Kimura T, Baschat AA. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 2007; 24(4): 257-266.
91. Benirschke K, Kaufmann P, Baergen RN. Pathology of the human placenta. 5th ed. New York: Springer; 2006; pp. 584-656.
92. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189(4): 1173-1177.
93. Wynn RM. The placenta in preeclampsia. Obstet Gynecol Annu 1977; 6: 191.
94. Salafia CM, Cowchock FS. Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol 1997; 14(8): 435-441.
95. Salafia CM, Parke AL. Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Rheum Dis Clin North Am 1997; 23(1): 85-97.
96. Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998; 179(1): 226-234.
97. Sebire NJ, Backos M, El Gaddal S, Goldin RD, Regan L. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients. Obstet Gynecol 2003; 101(2): 258-263.
98. Salafia CM, Pezzullo JC, Ghidini A, Lopez-Zeno JA, Whittington SS. Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. Placenta 1998; 19(1): 67-72.
99. Muller G, Philippe E, Lefakis P, et al. Placental lesions in gestosis. Anatomo-clinical study. Gynecol Obstet (Paris) 1971; 70(3): 309-315.
100. Schuhmann R, Geier G. Histomorphologic placenta findings in pregnancy toxemias. Contribution to the morphology of placenta insufficiency. Arch Gynakol 1972; 213(1): 31-47.
101. Holzl M, Luthje D, Seck-Ebersbach K. Aterations of the placenta in EPH-gestosis morphological findings and degree of severity of the disease (author's transl). Arch Gynakol 1974; 217(3): 315-334.
102. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1: 177-191.
103. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180(2 Pt 1): 499-506.
104. De Wolf F, Brosens I, Renaer M. Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension. Br J Obstet Gynaecol 1980; 87(8): 678-685.
105. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981; 88(9): 876-881.
106. Benirschke K, Kaufmann P, Baergen RN. Pathology of the human placenta. 5th ed. New York: Springer: 2006; pp. 42-120.
107. Aplin JD. Implantation, trophoblast differentiation and haemochorial placentation: mechanistic evidence in vivo and in vitro. J cell sci 1991; 99 (Pt 4): 681-692.
108. Kemp B, Kertschanska S, Kadyrov M, Rath W, Kaufmann P, Huppertz B. Invasive depth of extravillous trophoblast correlates with cellular phenotype: a comparison of intra-and extrauterine implantation sites. Histochem Cell Biol 2002; 117(5): 401-414.
109. Zybina TG, Frank HG, Biesterfeld S, Kaufmann P. Genome multiplication of extravillous trophoblast cells in human placenta in the course of differentiation and invasion into endometrium and myometrium. II. Mechanisms of polyploidization. Tsitologiia 2004; 46(7): 640-648.
110. Winterhager E, Kaufmann P, Gruemmer R. Cell-cell-communication during placental development and possible implications for trophoblast proliferation and differentiation. Placenta 2000; 21(Suppl A): S61-68.
111. Pijnenborg R, Bland JM, Robertson WB, Brosens I. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta 1983; 4(4): 397-413.
112. Pijnenborg R, Bland JM, Robertson WB, Dixon G, Brosens I. The pattern of interstitial trophoblastic invasion of the myometrium in early human pregnancy. Placenta 1981; 2(4): 303-316.
113. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69(1): 1-7.
114. Kadyrov M, Kingdom JC, Huppertz B. Divergent trophoblast invasion and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-onset preeclampsia/intrauterine growth restriction. Am J Obstet Gynecol 2006; 194(2): 557-563.
115. Lim KH, Zhou Y, Janatpour M, et al. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 1997; 151(6): 1809-1818.
116. Redline RW, Patterson P. Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast. Human pathology 1995; 26(6): 594-600.
117. DiFederico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol 1999; 155(1): 293-301.
118. Genbacev O, DiFederico E, McMaster M, Fisher SJ. Invasive cytotrophoblast apoptosis in pre-eclampsia. Hum Reprod 1999; 14(Suppl 2): 59-66.
119. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101(8): 669-674.
120. Harrington K, Goldfrad C, Carpenter RG, Campbell S. Transvaginal uterine and umbilical artery Doppler examination of 12-16 weeks and the subsequent development of pre-eclampsia and intrauterine growth retardation. Ultrasound Obstet Gynecol 1997; 9(2): 94-100.
121. Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH. Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002; 12(2): 78-88.
122. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992;80(2):283-235.
123. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997; 277(5332): 1669-1672.
124. Zhou Y, Genbacev O, Damsky CH, Fisher SJ. Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. J Reprod Immunol 1998; 39(1-2): 197-213.
125. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. The Journal of clinical investigation 1996; 97(2): 540-550.
126. Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). The Journal of clinical investigation 2000; 105(5):577-587.
127. Rajakumar A, Whitelock KA, Weissfeld LA, Daftary AR, Markovic N, Conrad KP. Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia. Biol Reprod 2001; 64(2): 499-506.
128. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxiainducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25(10): 763-769.
129. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. The Journal of clinical investigation 1999; 103(12): 1641-1650.
130. Dekker G, Robillard PY. The birth interval hypothesis-does it really indicate the end of the primipaternity hypothesis. J Reprod Immunol 2003; 59(2): 245-251.
131. Xia Y, Kellems RE. Is preeclampsia an autoimmune disease?. Clin Immunol 2009; 133(1): 1-12.
132. Billington WD. The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J Reprod Immunol 2003; 60(1): 1-11.
133. Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF. An epidemiologic study of contraception and preeclampsia. JAMA 1989; 262(22): 3143-3147.
134. Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol 2003; 188(5): 1241-1243.
135. Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D. Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. Hum Reprod 1991; 6(6): 791-798.
136. King A, Burrows TD, Hiby SE, et al. Surface expression of HLA-C antigen by human extravillous trophoblast. Placenta 2000; 21(4): 376-387.
137. Verma S, King A, Loke YW. Expression of killer cell inhibitory receptors on human uterine natural killer cells. Eur J Immunol 1997; 27(4): 979-983.
138. Lewis BJ, Croker S, Newton DJ, Lennon GP, Johnson PM, Christmas SE. Natural killer cell receptor expression by human first trimester decidual granular leukocytes and T-lymphocytes. Am J Reprod Immunol 2002; 48(2): 103-109.
139. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5(3): 201-214.
140. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344(12): 867-872.
141. Mogren I, Hogberg U, Winkvist A, Stenlund H. Familial occurrence of preeclampsia. Epidemiology 1999; 10(5): 518-522.
142. Engert S, Rieger L, Kapp M, Becker JC, Dietl J, Kammerer U. Profiling chemokines, cytokines and growth factors in human early pregnancy decidua by protein array. Am J Reprod Immunol 2007; 58(2): 129-137.
143. Moffett A, Hiby SE. How Does the maternal immune system contribute to the development of pre-eclampsia?. Placenta 2007; 28(Suppl A): S51-56.
144. Hiby SE, Walker JJ, O'Shaughnessy K M, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200(8): 957-965.
145. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009; 106(6): 1903-1908.
146. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457(7229): 557-561.
147. Sun JC, Lanier LL. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity?. Eur J Immunol 2009; 39(8): 2059-2064.
148. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447(7147): 972-978.
149. Little RE, Gladen BC. Levels of lipid peroxides in uncomplicated pregnancy: a review of the literature. Reprod Toxicol 1999; 13(5): 347-352.
150. Hung TH, Lo LM, Chiu TH, et al. A longitudinal study of oxidative stress and antioxidant status in women with uncomplicated pregnancies throughout gestation. Reprod Sci 2010; 17(4): 401-409.
151. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999; 222(3): 222-235.
152. Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996; 32(2): 157-169.
153. Morikawa S, Kurauchi O, Tanaka M, et al. Increased mitochondrial damage by lipid peroxidation in trophoblast cells of preeclamptic placentas. Biochem Mol Biol Int 1997; 41(4): 767-775.
154. Shibata E, Nanri H, Ejima K, et al. Enhancement of mitochondrial oxidative stress and up-regulation of antioxidant protein peroxiredoxin III/SP-22 in the mitochondria of human pre-eclamptic placentae. Placenta 2003; 24(6): 698- 705.
155. Walsh SW, Vaughan JE, Wang Y, Roberts LJ, 2nd. Placental isoprostane is significantly increased in preeclampsia. FASEB J 2000; 14(10): 1289-1296.
156. Sikkema JM, van Rijn BB, Franx A, et al. Placental superoxide is increased in pre-eclampsia. Placenta 2001; 22(4): 304-308.
157. Zusterzeel PL, Rutten H, Roelofs HM, Peters WH, Steegers EA. Protein carbonyls in decidua and placenta of preeclamptic women as markers for oxidative stress. Placenta 2001; 22(2-3): 213-219.
158. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. Journal of the Society for Gynecologic Investigation 2004; 11(6): 342-52.
159. Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000; 21(7): 597-602.
160. Vanderlelie J, Venardos K, Clifton VL, Gude NM, Clarke FM, Perkins AV. Increased biological oxidation and reduced anti-oxidant enzyme activity in pre-eclamptic placentae. Placenta 2005; 26(1): 53-58.
161. Burton GJ, Caniggia I. Hypoxia: implications for implantation to delivery-a workshop report. Placenta 2001; 22(Suppl A): S63-65.
162. Hung TH, Burton GJ. Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol 2006; 45(3): 189-200.
163. Lang U, Baker RS, Khoury J, Clark KE. Effects of chronic reduction in uterine blood flow on fetal and placental growth in the sheep. Am J Physiol Regul Integr Comp Physiol 2000; 279(1): R53-59.
164. Bloxam DL, Bullen BE, Walters BN, Lao TT. Placental glycolysis and energy metabolism in preeclampsia. Am J Obstet Gynecol 1987; 157(1): 97-101.
165. Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000; 183(1): 148-155.
166. Espinoza J, Sebire NJ, McAuliffe F, Krampl E, Nicolaides KH. Placental villus morphology in relation to maternal hypoxia at high altitude. Placenta 2001; 22(6): 606-608.
167. Reshetnikova OS, Burton GJ, Milovanov AP. Effects of hypobaric hypoxia on the fetoplacental unit: the morphometric diffusing capacity of the villous membrane at high altitude. Am J Obstet Gynecol 1994; 171(6): 1560- 1565.
168. Jauniaux E, Watson AL, Hempstock J, Bao YP, Skepper JN, Burton GJ. Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol 2000; 157(6): 2111-2122.
169. Jauniaux E, Jurkovic D, Campbell S. Current topic: in vivo investigation of the placental circulations by Doppler echography. Placenta 1995; 16(4): 323-331.
170. Jauniaux E, Ramsay B, Campbell S. Ultrasonographic investigation of placental morphologic characteristics and size during the second trimester of pregnancy. Am J Obstet Gynecol 1994; 170(1 Pt 1): 130-137.
171. Wang Y, Walsh SW. Increased superoxide generation is associated with decreased superoxide dismutase activity and mRNA expression in placental trophoblast cells in pre-eclampsia. Placenta 2001; 22(2-3): 206-212.
172. Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension 1996; 28(3): 488-493.
173. Hung TH, Skepper JN, Burton GJ. In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol 2001; 159(3): 1031-1043.
174. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ Res 2002; 90(12): 1274-1281.
175. Watson AL, Skepper JN, Jauniaux E, Burton GJ. Susceptibility of human placental syncytiotrophoblastic mitochondria to oxygen-mediated damage in relation to gestational age. J Clin Endocrinol Metab 1998; 83(5): 1697- 1705.
176. Harrison R. Structure and function of xanthine oxidoreductase: where are we now?. Free Radic Biol Med 2002; 33(6): 774-797.
177. Granger DN, Hollwarth ME, Parks DA. Ischemia-reperfusion injury: role of oxygen-derived free radicals. Acta Physiol Scand Suppl 1986; 548: 47-63.
178. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312(3): 159-163.
179. Nishino T, Nakanishi S, Okamoto K, et al. Conversion of xanthine dehydrogenase into oxidase and its role in reperfusion injury. Biochem Soc Trans 1997; 25(3): 783-786.
180. Many A, Westerhausen-Larson A, Kanbour-Shakir A, Roberts JM. Xanthine oxidase/dehydrogenase is present in human placenta. Placenta 1996; 17(5-6): 361-365.
181. Telfer JF, Thomson AJ, Cameron IT, Greer IA, Norman JE. Expression of superoxide dismutase and xanthine oxidase in myometrium, fetal membranes and placenta during normal human pregnancy and parturition. Hum Reprod 1997; 12(10): 2306-2312.
182. Many A, Hubel CA, Fisher SJ, Roberts JM, Zhou Y. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 2000; 156(1): 321-331.
183. Many A, Hubel CA, Roberts JM. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol 1996; 174(1 Pt 1): 288-291.
184. Muller MJ, Vollmar B, Friedl HP, Menger MD. Xanthine oxidase and superoxide radicals in portal triad crossclamping-induced microvascular reperfusion injury of the liver. Free Radic Biol Med 1996; 21(2): 189-197.
185. Tan S, Gelman S, Wheat JK, Parks DA. Circulating xanthine oxidase in human ischemia reperfusion. South Med J 1995; 88(4): 479-482.
186. Yildirim A, Altinkaynak K, Aksoy H, Sahin YN, Akcay F. Plasma xanthine oxidase, superoxide dismutase and glutathione peroxidase activities and uric acid levels in severe and mild pre-eclampsia. Cell Biochem Funct 2004; 22(4): 213-217.
187. Karabulut AB, Kafkasli A, Burak F, Gozukara EM. Maternal and fetal plasma adenosine deaminase, xanthine oxidase and malondialdehyde levels in pre-eclampsia. Cell Biochem Funct 2005; 23(4): 279-283.
188. Centlow M, Junus K, Nystrom H, et al. Perfusion of the human placenta with red blood cells and xanthine oxidase mimics preeclampsia in-vitro. Z Geburtshilfe Neonatol 2009; 213(3): 89-95.
189. Wang Y, Walsh SW. Placental mitochondria as a source of oxidative stress in pre-eclampsia. Placenta 1998; 19(8): 581-586.
190. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992; 284(Pt 1): 1-13.
191. Pitkanen S, Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. The Journal of clinical investigation 1996; 98(2): 345-351.
192. Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol 2005; 37(12): 2478-2503.
193. Weisiger RA, Fridovich I. Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J Biol Chem 1973; 248(13): 4793-4796.
194. McCord JM, Keele BB, Jr., Fridovich I. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. Proc Natl Acad Sci USA 1971; 68(5): 1024-1027.
195. Wiktor H, Kankofer M. Superoxide dismutase activity in normal and preeclamptic placentas. Ginekol Pol 1998; 69(12): 915-918.
196. Wang Y, Walsh SW. Antioxidant activities and mRNA expression of superoxide dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. J Soc Gynecol Investig 1996; 3(4): 179-184.
197. Hochstein P, Utley H. Hydrogen peroxide detoxication by glutathione peroxidase and catalase in rat liver homogenates. Mol Pharmacol 1968; 4(6): 574-579.
198. Madazli R, Benian A, Aydin S, Uzun H, Tolun N. The plasma and placental levels of malondialdehyde, glutathione and superoxide dismutase in pre-eclampsia. J Obstet Gynaecol 2002; 22(5): 477-480.
199. Poranen AK, Ekblad U, Uotila P, Ahotupa M. Lipid peroxidation and antioxidants in normal and pre-eclamptic pregnancies. Placenta 1996; 17(7): 401-405.
200. Mistry HD, Kurlak LO, Williams PJ, Ramsay MM, Symonds ME, Pipkin FB. Differential expression and distribution of placental glutathione peroxidases 1, 3 and 4 in normal and preeclamptic pregnancy. Placenta 2010; 31(5): 401-408.
201. Atamer Y, Kocyigit Y, Yokus B, Atamer A, Erden AC. Lipid peroxidation, antioxidant defense, status of trace metals and leptin levels in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 119(1): 60-66.
202. Walsh SW, Wang Y. Deficient glutathione peroxidase activity in preeclampsia is associated with increased placental production of thromboxane and lipid peroxides. Am J Obstet Gynecol 1993; 169(6): 1456-1461.
203. Vanderlelie J, Gude N, Perkins AV. Antioxidant gene expression in preeclamptic placentae: a preliminary investigation. Placenta 2008; 29(6): 519-522.
204. Funai EF, MacKenzie A, Kadner SS, Roque H, Lee MJ, Kuczynski E. Glutathione peroxidase levels throughout normal pregnancy and in pre-eclampsia. J Matern Fetal Neonatal Med 2002; 12(5): 322-326.
205. Levine RL. Oxidative modification of glutamine synthetase. I. Inactivation is due to loss of one histidine residue. J Biol Chem 1983; 258(19): 11823-11827.
206. Levine RL. Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med 2002; 32(9): 790-796.
207. Padmini E, Lavanya S, Uthra V. Preeclamptic placental stress and over expression of mitochondrial HSP70. Clin Chem Lab Med 2009; 47(9): 1073-1080.
208. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 1994; 233: 229-240.
209. Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995; 364(3): 279-282.
210. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994; 308(1): 89-95.
211. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991; 288(2): 481-417.
212. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298(2): 431-437.
213. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87(1): 315- 424.
214. Kossenjans W, Eis A, Sahay R, Brockman D, Myatt L. Role of peroxynitrite in altered fetal-placental vascular reactivity in diabetes or preeclampsia. Am J Physiol Heart Circ Physiol 2000; 278(4): H1311-1319.
215. Webster RP, Brockman D, Myatt L. Nitration of p38 MAPK in the placenta: association of nitration with reduced catalytic activity of p38 MAPK in pre-eclampsia. Mol Hum Reprod 2006; 12(11): 677-685.
216. Catala A. An overview of lipid peroxidation with emphasis in outer segments of photoreceptors and the chemiluminescence assay. Int J Biochem Cell Biol 2006; 38(9): 1482-1495.
217. Nigam S, Schewe T. Phospholipase A(2)s and lipid peroxidation. Biochim Biophys Acta 2000; 1488(1-2): 167-181.
218. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281(5381): 1309-12.
219. Wang Y, Walsh SW, Kay HH. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preeclampsia. Am J Obstet Gynecol 1992; 167(4 Pt 1): 946-949.
220. Borekci B, Aksoy H, Toker A, Ozkan A. Placental tissue cyclo-oxygenase 1 and 2 in pre-eclamptic and normal pregnancy. Int J Gynaecol Obstet 2006; 95(2): 127-131.
221. Biri A, Bozkurt N, Gunaydin G, Korucuoglu U, Durak I, Kavutcu M. Antioxidant enzyme activities and lipid peroxidation in preeclampsia. Int J Gynaecol Obstet 2007; 96(3): 196-197.
222. Walsh SW, Wang Y. Trophoblast and placental villous core production of lipid peroxides, thromboxane, and prostacyclin in preeclampsia. J Clin Endocrinol Metab 1995; 80(6): 1888-1893.
223. Borrego-Diaz E, Rosales JC, Proverbio T, et al. Effect of placental hypoxia on the plasma membrane Ca-ATPase (PMCA) activity and the level of lipid peroxidation of syncytiotrophoblast and red blood cell ghosts. Placenta 2008; 29(1): 44-50.
224. Walsh SW, Wang Y, Jesse R. Placental Production of Lipid Peroxides, Thromboxane, And Prostacyclin in Preeclampsia. Hypertension in Pregnancy 1996; 15(1): 101-111.
225. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002; 186(1): 158-166.
226. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998; 105(6): 632-640.
227. Hache S, Takser L, Lebellego F, et al. Alteration of calcium homeostasis in primary preeclamptic syncytiotrophoblasts: effect on calcium exchange in placenta. J Cell Mol Med 2011; 15(3): 654-667.
228. Cindrova-Davies T. Gabor Than Award Lecture 2008: pre-eclampsia-from placental oxidative stress to maternal endothelial dysfunction. Placenta 2009; 30(Suppl A): S55-65.
229. Chen Z, Gibson TB, Robinson F, et al. MAP kinases. Chem Rev 2001; 101(8): 2449-2476.
230. Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal 2005; 7(3-4): 472-481.
231. Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Charnock-Jones DS, Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol 2007; 170(5): 1511-1520.
232. Shin JK, Jeong YT, Jo HC, et al. Increased interaction between heat shock protein 27 and mitogen-activated protein kinase (p38 and extracellular signal-regulated kinase) in pre-eclamptic placentas. J Obstet Gynaecol Res 2009; 35(5): 888-894.
233. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 2003; 370(Pt 3): 1011-1017.
234. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells Review. Free Radic Res Commun 1992; 17(4): 221-237.
235. Aban M, Cinel L, Arslan M, et al. Expression of nuclear factor-kappa B and placental apoptosis in pregnancies complicated with intrauterine growth restriction and preeclampsia: an immunohistochemical study. Tohoku J Exp Med 2004; 204(3): 195-202.
236. Belkacemi L, Bedard I, Simoneau L, Lafond J. Calcium channels, transporters and exchangers in placenta: a review. Cell Calcium 2005; 37(1): 1-8.
237. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol 2010; (Suppl 1): S23-30.
238. Mattson MP, Chan SL. Calcium orchestrates apoptosis. Nat Cell Biol 2003; 5(12): 1041-1043.
239. Smaili S, Hirata H, Ureshino R, et al. Calcium and cell death signaling in neurodegeneration and aging. An Acad Bras Cienc 2009; 81(3): 467-475.
240. Hool LC. The L-type Ca(2+) channel as a potential mediator of pathology during alterations in cellular redox state. Heart Lung Circ 2009; 18(1): 3-10.
241. Droge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007; 6(3): 361-370.
242. Smith SC, Baker PN, Symonds EM. Placental apoptosis in normal human pregnancy. Am J Obstet Gynecol 1997; 177(1): 57-65.
243. Huppertz B, Frank HG, Reister F, Kingdom J, Korr H, Kaufmann P. Apoptosis cascade progresses during turnover of human trophoblast: analysis of villous cytotrophoblast and syncytial fragments in vitro. Lab Invest 1999; 79(12): 1687-1702.
244. Levy R, Nelson DM. To be, or not to be, that is the question. Apoptosis in human trophoblast. Placenta 2000; 21(1): 1-13.
245. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA. Placental apoptosis in preeclampsia. Obstet Gynecol 2000; 96(2): 271-276.
246. Leung DN, Smith SC, To KF, Sahota DS, Baker PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001; 184(6): 1249-1250.
247. Jones CJ, Fox H. An ultrastructural and ultrahistochemical study of the human placenta in maternal pre-eclampsia. Placenta 1980; 1(1): 61-76.
248. Huppertz B, Kingdom JC. Apoptosis in the trophoblast--role of apoptosis in placental morphogenesis. J Soc Gynecol Investig 2004; 11(6): 353-362.
249. Huppertz B, Kingdom J, Caniggia I, et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003; 24(2-3): 181-190.
250. Redman CWG, Sargent IL, Roberts JM, et al. Immunology of Normal Pregnancy and Preeclampsia. Chesley's Hypertensive Disorders in Pregnancy. 3rd ed. San Diego: Academic Press 2009; pp. 129-142.
251. Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW, Burton GJ. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006; 169(2): 400-404.
252. Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol 2004; 164(3): 1049-1061.
253. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12(6): 642-649.
254. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111(5): 649-658.
255. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997; 349(9061): 1285-1258.
256. Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999; 45(2): 184-188.
257. Perkins AV, Linton EA, Eben F, Simpson J, Wolfe CD, Redman CW. Corticotrophin-releasing hormone and corticotrophin-releasing hormone binding protein in normal and pre-eclamptic human pregnancies. Br J Obstet Gynaecol 1995; 102(2): 118-122.
258. Mise H, Sagawa N, Matsumoto T, et al. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. J Clin Endocrinol Metab 1998; 83(9): 3225-3229.
259. Redman CW, Sargent IL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 2008; 29(Suppl A): S73-77.
260. Aly AS, Khandelwal M, Zhao J, Mehmet AH, Sammel MD, Parry S. Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia. Am J Obstet Gynecol 2004; 190(1): 252-258.
261. Lok CA, Van Der Post JA, Sargent IL, et al. Changes in microparticle numbers and cellular origin during pregnancy and preeclampsia. Hypertens Pregnancy 2008; 27(4): 344-360.
262. Cockell AP, Learmont JG, Smarason AK, Redman CW, Sargent IL, Poston L. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol 1997; 104(2): 235-240.
263. Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportation in human pregnancy--its relevance for pre-eclampsia. Placenta 1999; 20(7): 531-539.
264. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350(7): 672-683.
265. Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004; 50(9): 1702-1703.
266. Wathen KA, Tuutti E, Stenman UH, et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006; 91(1): 180- 184.
267. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190(6): 1541-1547.
268. Nevo O, Soleymanlou N, Wu Y, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291(4): R1085-1093.
269. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93(1): 260-266.
270. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355(10): 992-1005.
271. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277(46): 43799- 43808.
272. Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres Clin Obstet Gynaecol 1994; 8(2): 443-468.
273. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161(5): 1200-4.
274. Deng L, Bremme K, Hansson LO, Blomback M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994; 84(6): 941-945.
275. Clark BA, Halvorson L, Sachs B, Epstein FH. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol 1992; 166(3): 962-968.
276. Lyall F, Greer IA, Boswell F, Macara LM, Walker JJ, Kingdom JC. The cell adhesion molecule, VCAM-1, is selectively elevated in serum in pre-eclampsia: does this indicate the mechanism of leucocyte activation?. Br J Obstet Gynaecol 1994; 101(6): 485-487.
277. Minakami H, Takahashi T, Izumi A, Tamada T. Increased levels of plasma thrombomodulin in preeclampsia. Gynecol Obstet Invest 1993; 36(4): 208-210.
278. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991; 4(8): 700-708.
279. Friedman SA, Schiff E, Emeis JJ, Dekker GA, Sibai BM. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995; 172(1Pt 1): 202-203.
280. Austgulen R, Lien E, Vince G, Redman CW. Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 71(1): 53-58.
281. Redman CWG, Sargent IL. Preeclampsia and the systemic inflammatory response. Seminars in Nephrology 2004; 24(6): 565-570.
282. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6): 448-454.
283. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M, Salier JP. Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm Res 2001; 50(8): 383- 390.
284. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982; 389: 406-418.
285. Mihu D, Costin N, Mihu CM, Blaga LD, Pop RB. C-reactive protein, marker for evaluation of systemic inflammatory response in preeclampsia. Rev Med Chir Soc Med Nat Iasi 2008; 112(4): 1019-1025.
286. Belo L, Santos-Silva A, Rumley A, et al. Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. BJOG 2002; 109(11): 1250-1255.
287. Morgan T, Craven C, Nelson L, Lalouel JM, Ward K. Angiotensinogen T235 expression is elevated in decidual spiral arteries. J Clin Invest 1997; 100(6): 1406-1415.
288. von Versen-Hoeynck FM, Hubel CA, Gallaher MJ, Gammill HS, Powers RW. Plasma levels of inflammatory markers neopterin, sialic acid, and C-reactive protein in pregnancy and preeclampsia. Am J Hypertens 2009; 22(6): 687-692.
289. Derzsy Z, Prohaszka Z, Rigo J, Jr., Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47(7-8): 1500-1506.
290. Lynch AM, Salmon JE. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010; 31(7): 561-567.
291. Lox CD, Dorsett MM, Hampton RM. Observations on clotting activity during pre-eclampsia. Clin Exp Hypertens B 1983; 2(2): 179-190.
292. Auer J, Camoin L, Guillonneau F, et al. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteomics 2010; 73(5): 1004-1017.
293. Johansen KA, Williams JH, Stark JM. Acute-phase C56-forming ability and concentrations of complement components in normotensive and hypertensive pregnancies. Br J Obstet Gynaecol 1981; 88(5): 504-512.
294. Margarson MP, Soni N. Serum albumin: touchstone or totem?. Anaesthesia 1998; 53(8): 789-803.
295. Lorentzen B, Endresen MJ, Clausen T, Henriksen T. Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia. Hypertension in Pregnancy 1994; 13(1): 103-109.
296. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. Am J Obstet Gynecol 1996; 174(3): 975-982.
297. Ogura K, Miyatake T, Fukui O, Nakamura T, Kameda T, Yoshino G. Low-density lipoprotein particle diameter in normal pregnancy and preeclampsia. J Atheroscler Thromb 2002; 9(1): 42-47.
298. Qiu C, Phung TT, Vadachkoria S, Muy-Rivera M, Sanchez SE, Williams MA. Oxidized low-density lipoprotein (Oxidized LDL) and the risk of preeclampsia. Physiol Res 2006; 55(5): 491-500.
299. Harris HW, Gosnell JE, Kumwenda ZL. The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res 2000; 6(6): 421-30.
300. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999; 10(1):19-29.
301. Stepan H, Philipp A, Reiche M, et al. Serum levels of the adipokine lipocalin-2 are increased in preeclampsia. J Endocrinol Invest 2010; 33(9): 626-632.
302. Fasshauer M, Seeger J, Waldeyer T, et al. Serum levels of the adipokine adipocyte fatty acid-binding protein are increased in preeclampsia. Am J Hypertens 2008; 21(5): 582-586.
303. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ?. A review article. Dig Dis Sci 2009; 54(9): 1847-1856.
304. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115(5): 911-919.
305. Martinez-Abundis E, Gonzalez-Ortiz M, Pascoe-Gonzalez S. Serum leptin levels and the severity of preeclampsia. Arch Gynecol Obstet 2000; 264(2): 71-73.
306. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005; 174(6): 3137-3142.
307. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and Inflammation. Curr Immunol Rev 2008; 14(2): 70-79.
308. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365(9461): 785-99.
309. Scott JR. Magnesium sulfate for mild preeclampsia. Obstet Gynecol 2003; 101(2): 213.
310. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003; 101(2): 217-220.
311. Deruelle P, Girard JM, Coutty N, Subtil D. Prevention of preeclampsia. Ann Fr Anesth Reanim 2010; 29(3): e31-35.
312. Sergio F, Maria Clara D, Gabriella F, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 2006; 25(2): 115-127.
313. Alguel G, Vormittag R, Simanek R, et al. Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low-molecular-weight heparin (LMWH) during pregnancy. Thromb Haemost 2006; 96(3): 28525-28529.
314. Sorensen TK, Williams MA, Lee IM, Dashow EE, Thompson ML, Luthy DA. Recreational physical activity during pregnancy and risk of preeclampsia. Hypertension 2003; 41(6): 1273-1280.
315. Yeo S, Davidge ST. Possible beneficial effect of exercise, by reducing oxidative stress, on the incidence of preeclampsia. J Womens Health Gend Based Med 2001; 10(10): 983-989.
316. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 1998; 92(5): 883- 889.
317. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate?. The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359(9321): 1877-1890.
318. Grill S, Rusterholz C, Zanetti-Dallenbach R, et al. Potential markers of preeclampsia--a review. Reprod Biol Endocrinol 2009; 7: 70.
319. Martin JN, Jr., Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105(2): 246-254.
320. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003; (3): CD002863.
321. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007; (1): CD002252.
322. Sibai BM. Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol 2008; 20(2): 102-106.
323. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; (2): CD004659.
324. Coomarasamy A, Papaioannou S, Gee H, Khan KS. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol 2001; 98(5Pt1): 861-866.
325. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a metaanalysis of individual patient data. Lancet 2007; 369(9575): 1791-1798.
326. Hermida RC, Ayala DE, Calvo C, et al. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension 2003; 41(6): 1259-1267.
327. Hermida RC, Ayala DE, Iglesias M, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension 1997; 30(3 Pt 2): 589-595.
328. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7(1): 58- 64.
329. Belizan JM, Villar J, Repke J. The relationship between calcium intake and pregnancy-induced hypertension: up-todate evidence. Am J Obstet Gynecol 1988; 158(4): 898-902.
330. Villar J, Repke JT. Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations. Am J Obstet Gynecol 1990; 163(4 Pt 1): 1124-1131.
331. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354(17): 1796-1806.
332. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367(9517): 1145-1154.
333. Talaulikar VS, Manyonda IT. Vitamin C as an antioxidant supplement in women's health: a myth in need of urgent burial. Eur J Obstet Gynecol Reprod Biol 2011; 157(1): 10-13.
334. Rossi AC, Mullin PM. Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis. Eur J Obstet Gynecol Reprod Biol 2011; 158(1): 9-16.
335. Kalpdev A, Saha SC, Dhawan V. Vitamin C and E Supplementation Does Not Reduce the Risk of Superimposed PE in Pregnancy. Hypertens Pregnancy 2011; 30(4): 447-56.
336. Talaulikar V, Manyonda I. The myth of vitamins C and E for the prevention of preeclampsia: just when will the penny drop?. Am J Obstet Gynecol 2010; 203(6): e7-8.
337. Yeo S, Davidge S, Ronis DL, Antonakos CL, Hayashi R, O'Leary S. A comparison of walking versus stretching exercises to reduce the incidence of preeclampsia: a randomized clinical trial. Hypertens Pregnancy 2008; 27(2): 113- 130.
338. Aversa S, Pellegrino S, Barberi I, Reiter RJ, Gitto E. Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. J Matern Fetal Neonatal Med 2011 [May 11 Epub ahead of print].
339. Poston L, Igosheva N, Mistry HD, et al. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr 2011; 94(6): 198; 0S-5S.
340. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010; 5: 173-192.
341. Karumanchi SA, Lindheimer MD. Advances in the understanding of eclampsia. Curr Hypertens Rep 2008; 10(4): 305-312.
342. Williams KP, Wilson S. Ethnic variation in the incidence of HELLP syndrome in a hypertensive pregnant population. J Perinat Med 1997; 25(6): 498-501.
343. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994; 309(6966): 1395-1400.
344. Noraihan MN, Sharda P, Jammal AB. Report of 50 cases of eclampsia. J Obstet Gynaecol Res. 2005;31(4):302-309.
345. Airoldi J, Weinstein L. Clinical significance of proteinuria in pregnancy. Obstet Gynecol Surv 2007; 62(2): 117-124.
346. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004; 103(5 Pt 1): 981-91.
347. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005; 105(2): 402-410.
348. Katz VL, Farmer R, Kuller JA. Preeclampsia into eclampsia: toward a new paradigm. Am J Obstet Gynecol 2000; 182(6): 1389-1396.
349. Sheth SS, Chalmers I. Magnesium for preventing and treating eclampsia: time for international action. Lancet 2002; 359(9321): 1872-1873.
350. Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2001; (1): CD002960.
351. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003; (4): CD000128.
352. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003; (4): CD000127.
353. Aaserud M, Lewin S, Innvaer S, et al. Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia. BMC Health Serv Res 2005; 1: 5-68.
354. Sevene E, Lewin S, Mariano A, et al. System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and Zimbabwe. BMJ 2005; 331(7519): 765-769.
355. Brown MA, Buddle ML. Hypertension in pregnancy: maternal and fetal outcomes according to laboratory and clinical features. Med J Aust 1996; 165(7): 360-365.
356. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169(4): 1000-1006.
357. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. Lancet 2010; 375(9714): 594-605.
358. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000; 183(2): 444-448.
359. Osmanagaoglu MA, Osmanagaoglu S, Ulusoy H, Bozkaya H. Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital. Sao Paulo Med J 2006; 124(2): 85-89.
360. Martin JN, Jr., Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006; 195(4): 914-934.
361. Sibai BM, Ramadan MK, Chari RS, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995; 172(1 Pt 1): 125-129.
362. Sullivan CA, Magann EF, Perry KG, Jr., Roberts WE, Blake PG, Martin JN, Jr. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 1994; 171(4): 940-943.
363. Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000; 182(2): 307- 312.
364. Martin JN, Jr., Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999; 180(6 Pt 1): 1373-1384.
365. Cavkaytar S, Ugurlu EN, Karaer A, Tapisiz OL, Danisman N. Are clinical symptoms more predictive than laboratory parameters for adverse maternal outcome in HELLP syndrome?. Acta Obstet Gynecol Scand 2007; 86(6): 648-651.
366. Zeeman GG, Fleckenstein JL, Twickler DM, Cunningham FG. Cerebral infarction in eclampsia. Am J Obstet Gynecol 2004; 190(3): 714-720.
367. Zeidman LA, Videnovic A, Bernstein LP, Pellar CA. Lethal pontine hemorrhage in postpartum syndrome of hemolysis, elevated liver enzyme levels, and low platelet count. Arch Neurol 2005; 62(7): 1150-1153.
368. Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, Martin JN, Jr. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1999; 181(4): 924- 928.
369. Araujo AC, Leao MD, Nobrega MH, et al. Characteristics and treatment of hepatic rupture caused by HELLP syndrome. Am J Obstet Gynecol 2006; 195(1): 129-133.
370. Reck T, Bussenius-Kammerer M, Ott R, Muller V, Beinder E, Hohenberger W. Surgical treatment of HELLP syndrome-associated liver rupture--an update. Eur J Obstet Gynecol Reprod Biol 2001; 99(1): 57-65.
371. Miguil M, Chekairi A. Eclampsia, study of 342 cases. Hypertens Pregnancy 2008; 27(2): 103-111.
372. Sibai BM, Caritis S, Hauth J. What we have learned about preeclampsia. Semin Perinatol 2003; 27(3): 239-246.
373. Fonseca JE, Mendez F, Catano C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193(5): 1591-1598.
374. Moulin B, Hertig A, Rondeau E. Kidney and preeclampsia. Ann Fr Anesth Reanim 2010; 29(4): e83-90.
375. Roberts JM, Lain KY. Recent Insights into the pathogenesis of pre-eclampsia. Placenta 2002; 23(5): 359-372.
376. Lafayette RA, Druzin M, Sibley R, et al. Nature of glomerular dysfunction in pre-eclampsia. Kidney Int 1998; 54(4): 1240-1249.
377. Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196(4): 320e1-7.
378. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16(6): 1733-41.
379. Nakamura T, Ushiyama C, Suzuki S, et al. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000; 320(2): 112-6.
380. Harkness UF, Mari G. Diagnosis and management of intrauterine growth restriction. Clin Perinatol 2004; 31(4): 743- 764.
381. Lorenzi T, Marzioni D, Giannubilo S, et al. Expression patterns of two serine protease HtrA1 forms in human placentas complicated by preeclampsia with and without intrauterine growth restriction. Placenta 2009; 30(1): 35-40.
382. Rasmussen S, Irgens LM. History of fetal growth restriction is more strongly associated with severe rather than milder pregnancy-induced hypertension. Hypertension 2008; 51(4): 1231-1238.
383. Burton G.J, Cindrova-Davies T, Charnock-Jones D.S. Placental Endoplasmic Reticulum Stress and Oxidative Stress in the Pathophysiology of Unexplained Intrauterine Growth Restriction and Early Onset Preeclampsia. Placenta 2009; (30 Suppl A): S43-48.
384. Newhouse SM, Davidge ST, Winkler-Lowen B, Demianczuk N, Guilbert LJ. In vitro differentiation of villous trophoblasts from pregnancies complicated by intrauterine growth restriction with and without pre-eclampsia. Placenta 2007; 28(10): 999-1003.
385. Mari G, Hanif F, Kruger M. Sequence of cardiovascular changes in IUGR in pregnancies with and without preeclampsia. Prenat Diagn 2008; 28(5): 377-383.
386. Roberts JM, Catov JM. Preeclampsia more than 1 disease: or is it?. Hypertension 2008; 51(4): 989-990.
387. Shear RM, Rinfret D, Leduc L. Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction?. Am J Obstet Gynecol 2005; 192(4): 1119-1125.
388. Tranquilli AL, Giannubilo SR. Blood pressure is elevated in normotensive pregnant women with intrauterine growth restriction. Eur J Obstet Gynecol Reprod Biol 2005; 122(1): 45-48.
389. Churchill D, Perry IJ, Beevers DG. Ambulatory blood pressure in pregnancy and fetal growth. Lancet 1997; 349(9044): 7-10.
390. Mitani M, Matsuda Y, Makino Y, Akizawa Y, Ohta H. Clinical features of fetal growth restriction complicated later by preeclampsia. J Obstet Gynaecol Res 2009; 35(5): 882-887.
391. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30(4): 293-308.
392. Hack M, Flannery DJ, Schluchter M, Cartar L, Borawski E, Klein N. Outcomes in young adulthood for very-lowbirth- weight infants. N Engl J Med 2002; 346(3): 149-157.
393. Briana DD, Gourgiotis D, Boutsikou M, et al. Perinatal bone turnover in term pregnancies: the influence of intrauterine growth restriction. Bone 2008; 42(2): 307-313.
394. Chunga Vega F, Gomez de Tejada MJ, Gonzalez Hachero J, Perez Cano R, Coronel Rodriguez C. Low bone mineral density in small for gestational age infants: correlation with cord blood zinc concentrations. Arch Dis Child Fetal Neonatal Ed 1996; 75(2): F126-129.
395. Helin I, Landin LA, Nilsson BE. Bone mineral content in preterm infants at age 4 to 16. Acta Paediatr Scand 1985; 74(2): 264-267.
396. Fall C, Hindmarsh P, Dennison E, Kellingray S, Barker D, Cooper C. Programming of growth hormone secretion and bone mineral density in elderly men: a hypothesis. J Clin Endocrinol Metab 1998; 83(1): 135-139.
397. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335(7627): 974.